Status:
COMPLETED
Effects of Cyclosporine A on Pancreatic Insulin Secretion
Lead Sponsor:
University of Oslo School of Pharmacy
Conditions:
Chronic Renal Failure
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Our primary aim is to investigate if cyclosporine A reduces insulin secretion.
Detailed Description
Our primary aim is to investigate if cyclosporine A may reduce insulin secretion by 20% or more. In order to get cyclosporine A naïve patients we will perform this investigation in dialysis patients o...
Eligibility Criteria
Inclusion
- Renal failure patients on dialysis which is planned to receive a renal transplant
Exclusion
- Age below 18 years or above 75 years
- Pregnancy
- Breast feeding mothers
- Diabetes mellitus /WHO criteria)
- Dialysis treatment less than 2 months
- Serious coronary heart disease
- Unstable angina pectoris
- Recent acute infarction (less than 3 months)
- Non-compensated heart failure
- Simultaneous treatment with glucocorticosteroids (e.g. prednisolone, dexamethasone), diltiazem, verapamil, erythromycin, clarithromycin, telithromycin, rifampicin, fluconazole, itraconazole, ketoconazole, voriconazole, indinavir, nelfinavir, ritonavir, nefazodone, bosentan, carbamazepine, St. John's worth, grapefruit.
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00139035
Start Date
April 1 2005
Last Update
November 2 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rikshospitalet, Section of Nephrology
Oslo, Oslo County, Norway, 0027